Iron deficiency and supplementation in patients with heart failure: Results from the IRON-HF international survey.
Heart Failure Guidelines
Heart failure
International survey
Iron deficiency
Iron supplementation
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
04 Jul 2024
04 Jul 2024
Historique:
revised:
22
05
2024
received:
26
01
2024
accepted:
13
06
2024
medline:
4
7
2024
pubmed:
4
7
2024
entrez:
4
7
2024
Statut:
aheadofprint
Résumé
Iron deficiency (ID) is common in patients with heart failure (HF) and is associated with poor outcomes, regardless of anaemia status. Iron supplementation has been demonstrated to improve exercise capacity and quality of life in patients with HF with an ejection fraction <50% and ID. This survey aimed to provide data on real-world practices related to ID screening and management. We designed and distributed an online survey (23 questions) regarding ID screening and management in the HF setting. Overall, 256 cardiologists completed the survey (59.8% male, mostly between 30 and 50 years). The majority of physicians defined ID according to the most recent HF recommendations (98.4%) and reported screening for ID in more than half of their patients (68.4%). However, only 54.3% of the respondents performed periodic screening (every 6 months to 1 year). A total of 93.0% of participants prescribed and/or administered iron supplementation, using intravenous iron as the preferred method of administration (86.3%). After iron supplementation, 96.1% of the respondents reassessed ID, most frequently at 3-6 months (67.6%). Most physicians (93.8%) perceived ID as an underestimated comorbidity in HF. Cardiologists' age, training status, subspecialty and work setting (academic vs. non-academic hospitals) were associated with heterogeneity in the answers. The results of this survey highlight the need for more consistent strategies of ID screening and treatment for patients with HF.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Savarese G, von Haehling S, Butler J, Cleland JGF, Ponikowski P, Anker SD. Iron deficiency and cardiovascular disease. Eur Heart J 2023;44:14–27. https://doi.org/10.1093/eurheartj/ehac569
Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, et al.; NHLBI Heart Failure Clinical Research Network. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: The IRONOUT HF randomized clinical trial. JAMA 2017;317:1958–1966. https://doi.org/10.1001/jama.2017.5427
Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al.; FAIR‐HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436–2448. https://doi.org/10.1056/NEJMoa0908355
Ponikowski P, van Veldhuisen DJ, Comin‐Colet J, Ertl G, Komajda M, Mareev V, et al.; CONFIRM‐HF Investigators. Beneficial effects of long‐term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency†. Eur Heart J 2015;36:657–668. https://doi.org/10.1093/eurheartj/ehu385
van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Böhm M, Doletsky A, et al.; EFFECT‐HF Investigators. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 2017;136:1374–1383. https://doi.org/10.1161/CIRCULATIONAHA.117.027497
Ponikowski P, Kirwan BA, Anker SD, McDonagh T, Dorobantu M, Drozdz J, et al.; AFFIRM‐AHF investigators. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: A multicentre, double‐blind, randomised, controlled trial. Lancet 2020;396:1895–1904. https://doi.org/10.1016/S0140‐6736(20)32339‐4
Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, et al.; IRONMAN Study Group. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): An investigator‐initiated, prospective, randomised, open‐label, blinded‐endpoint trial. Lancet 2022;400:2199–2209. https://doi.org/10.1016/S0140‐6736(22)02083‐9
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129–2200. https://doi.org/10.1093/eurheartj/ehw128
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2022;24:4–131. https://doi.org/10.1002/ejhf.2333
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 2022;79:e263–e421. https://doi.org/10.1016/j.jacc.2021.12.012
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al.; ESC Scientific Document Group. Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2024;26:5–17. https://doi.org/10.1002/ejhf.3024
Ponikowski P, Mentz RJ, Hernandez AF, Butler J, Khan MS, van Veldhuisen DJ, et al. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: An individual patient data meta‐analysis. Eur Heart J 2023;44:5077–5091. https://doi.org/10.1093/eurheartj/ehad586
Anker SD, Khan MS, Butler J, von Haehling S, Jankowska EA, Ponikowski P, et al. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta‐analysis. Eur J Heart Fail 2023;25:1080–1090. https://doi.org/10.1002/ejhf.2860
Graham FJ, Pellicori P, Kalra PR, Ford I, Bruzzese D, Cleland JGF. Intravenous iron in patients with heart failure and iron deficiency: An updated meta‐analysis. Eur J Heart Fail 2023;25:528–537. https://doi.org/10.1002/ejhf.2810
Vukadinović D, Abdin A, Emrich I, Schulze PC, von Haehling S, Böhm M. Efficacy and safety of intravenous iron repletion in patients with heart failure: a systematic review and meta‐analysis. Clin Res Cardiol 2023;112:954–966. https://doi.org/10.1007/s00392‐023‐02207‐2.
Savarese G, Kishi T, Vardeny O, Adamsson Eryd S, Bodegård J, Lund LH, et al. Heart failure drug treatment – inertia, titration, and discontinuation: A multinational observational study (EVOLUTION HF). JACC Heart Fail 2023;11:1–14. https://doi.org/10.1016/j.jchf.2022.08.009
Lindberg F, Lund LH, Benson L, Linde C, Orsini N, Carrero JJ, et al. Iron deficiency in heart failure: Screening, prevalence, incidence and outcome data from the Swedish Heart Failure Registry and the Stockholm CREAtinine Measurements collaborative project. Eur J Heart Fail 2023;25:1270–1280. https://doi.org/10.1002/ejhf.2879
Pezel T, Audureau E, Mansourati J, Baudry G, Ben Driss A, Durup F, et al. Diagnosis and treatment of iron deficiency in heart failure: OFICSel study by the French Heart Failure Working Group. ESC Heart Fail 2021;8:1509–1521. https://doi.org/10.1002/ehf2.13245
Papadopoulou C, Reinhold J, Grüner‐Hegge N, Kydd A, Bhagra S, Parameshwar KJ, et al. Prognostic value of three iron deficiency definitions in patients with advanced heart failure. Eur J Heart Fail 2023;25:2067–2074. https://doi.org/10.1002/ejhf.2949
Packer M, Anker SD, Butler J, Cleland JGF, Kalra PR, Mentz RJ, et al. Redefining iron deficiency in patients with chronic heart failure. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.124.068883 Published online ahead of print 11/05/24.
Packer M, Anker SD, Butler J, Cleland JGF, Kalra PR, Mentz RJ, et al. Critical re‐evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure. Eur J Heart Fail. https://doi.org/10.1002/ejhf.3237 Published online ahead of print 10/05/24.
Becher PM, Schrage B, Benson L, Fudim M, Corovic Cabrera C, Dahlström U, et al. Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: Data from the Swedish Heart Failure Registry. Eur J Heart Fail 2021;23:1844–1854. https://doi.org/10.1002/ejhf.2338
McDonagh TA, Gardner RS, Lainscak M, Nielsen OW, Parissis J, Filippatos G, et al. Heart Failure Association of the European Society of Cardiology specialist heart failure curriculum. Eur J Heart Fail 2014;16:151–162. https://doi.org/10.1002/ejhf.41
Fitzsimons S, Yeo TJ, Ling LH, Sim D, Leong KTG, Yeo PSD, et al. Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype. ESC Heart Fail 2021;8:4572–4583. https://doi.org/10.1002/ehf2.13617